What is MYNZ's current stock price?

MYNZ (Mainz Biomed B.V.) is currently trading at $3.59 with a market cap of $14.7M.

What sector is Mainz Biomed B.V. in?

Mainz Biomed B.V. (MYNZ) operates in the Healthcare sector, specifically in the Medical - Diagnostics & Research industry.

InvestLog

MYNZ Mainz Biomed B.V.

Healthcare

$3.59+0.84%ClosedMarket Cap: $14.7M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

8.56

P/S

145.36

EV/EBITDA

-4.97

DCF Value

$-1.68

FCF Yield

-13.3%

Div Yield

0.0%

Margins & Returns

Gross Margin

100.0%

Operating Margin

-2723.5%

Net Margin

-2937.8%

ROE

-244.2%

ROA

-109.1%

ROIC

-165.6%

Financials

View All

Period	Revenue	Net Income	EPS
Q4 null	$250.4K	$-7.9M	$—
FY null	$537.1K	$-16.2M	$—
Q2 null	$286.7K	$-8.3M	$—
Q4 null	$373.2K	$-10.6M	$—

Analyst Ratings

View All

Consensus

Hold

Target (Consensus)

$—

Target (Median)

$—

Target Range

$— - $—

0 Strong Buy0 Buy1 Hold0 Sell0 Strong Sell

Trading Activity

Insider Trades

View All

NATAN DAVIDdirector

SellThu May 21

Lazar David E.director, 10 percent owner, officer: Chief Executive Officer

SellTue Apr 28

Lazar David E.director

SellTue Mar 03

Lazar David E.director

SellTue Mar 03

Tibbitts Gregory Jdirector

SellThu Feb 19

Company Info

Sector

Healthcare

Industry

Medical - Diagnostics & Research

Country

Exchange

—

Beta

0.32

Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.

Peers

GBS

IBO